Please assess the completion status of the following clinical trial:

Trial Title: Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Adult (age at least 18 years old at moment of transplantation)~* Able to take oral medication~* Histologic diagnosis of lymphocytic bronchiolitis or bronchitis ('grade B') without concurrent acute cellular allograft rejection 'grade A' ≥2~Exclusion Criteria:~* Severe suture problems (e.g. airway stenosis) requiring lasering or stenting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).